Selkirk Pharma, a US pharmaceutical manufacturer specialising in fill and finish of injectables, has appointed Colleen Dixon as the company's new CEO.
Colleen who, formerly served as the Vice President of Programme Management at Selkirk, succeeds Patrick Haffey, the founder, Chair and CEO of the company.
Dixon has an extensive background in biopharma research and development, manufacturing and leadership, and will bring a wealth of knowledge to assist the company in its growth and development of industry partnerships.
With more than 30 years of experience in the pharmaceutical industry, Colleen has held senior leadership roles at AstraZeneca, Baxter Biopharma Solutions and Eli Lilly.
Her expertise in strategic planning, capital expansions, organisational change management and portfolio management — combined with direct manufacturing leadership in both drug product and drug substance spaces — positions her to effectively lead Selkirk Pharma in its next phase of growth.
Chair of the Board for Selkirk Pharma, Jim Bell, commented: “With Colleen’s exceptional leadership skills, extensive industry experience, and visionary approach, we are confident that she will steer our company towards growth and success. Colleen's proven track record of innovation and commitment to excellence aligns perfectly with our strategic vision. We look forward to supporting her in this exciting new chapter for Selkirk."
